Elutia Inc. Announces Sale of SimpliDerm Business for $7.7M

What Happened
Elutia Inc. announced on Form 8-K that it completed the sale of its SimpliDerm human acellular dermis (hADM) business to Cellution Biologics on August 17, 2026. The buyer paid $7.7 million at closing; the purchase price may be adjusted after a post‑closing inventory valuation and the deal includes up to $3.0 million in contingent payments payable over the next 18 months tied to technology transfer and commercial milestones. The SimpliDerm assets made up substantially all of Elutia’s Women’s Health segment.

Key Details

• Closing date: August 17, 2026; Asset Purchase Agreement dated July 16, 2026.
• Cash received at closing: $7.7 million. Potential additional consideration: up to $3.0 million contingent (inventory adjustment and milestone payments).
• Transitional and contract terms: Elutia agreed to a 5‑year non‑competition covenant related to hADM products and to provide transition services for up to six months.
• Financing/lien: Elutia amended its Loan and Security Agreement to release the lien on the sold assets.
• Pro forma financial information as of June 30, 2026 is filed with the 8‑K (Exhibit 99.2).

Why It Matters
This transaction divests Elutia’s SimpliDerm hADM business—substantially all of its Women’s Health assets—bringing immediate cash of $7.7M and potential additional payments that depend on inventory valuation and milestones. Investors should review the filed pro forma financials to see how the sale affects Elutia’s reported results and balance sheet, and note the five‑year non‑compete and transitional obligations that could affect future strategy in related product areas. The company’s 8‑K also highlights forward‑looking risks tied to the contingent payments and post‑closing adjustments.